The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
tocilizumab-aazg · Injection, Solution, Concentrate
3 marketed package NDCs · 1 active manufacturer
Most dispensed: TOCILIZUMAB 162 mg/.9mL · Injection, Solution · #1 syringe, glass/carton / .9 ml in 1 syringe, glass
What changed in the last 90 days
Every detected change for tocilizumab-aazg, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
Same drug class
Other molecules FDA puts in Interleukin-6 Receptor Antagonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Tocilizumab-aazg in shortage right now?
- No. FDA does not currently list Tocilizumab-aazg in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Tocilizumab-aazg?
- 1 company has marketed Tocilizumab-aazg in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Tocilizumab-aazg cost?
- The typical pharmacy pays about $821.00 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.